Analyst Rating Update on bluebird bio (BLUE)

bluebird bio (NASDAQ:BLUE) : The consensus on bluebird bio (NASDAQ:BLUE) based on 12 analyst recommendation on the company stock is 1.5, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 9 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

bluebird bio (NASDAQ:BLUE) : 11 Wall Street analysts covering bluebird bio (NASDAQ:BLUE) believe that the average level the stock could reach for the short term is $89.55. The maximum price target given is $164 and the minimum target for short term is around $42, hence the standard deviation is calculated at $37.1.

For the current week, the company shares have a recommendation consensus of Buy. Also, Cantor Fitzgerald initiates coverage on bluebird bio (NASDAQ:BLUE) The brokerage firm has issued a Hold rating on the shares. The Analysts at the ratings agency announces the price target to $42 per share. The rating by the firm was issued on June 2, 2016.

bluebird bio (NASDAQ:BLUE): stock turned positive on Tuesday. Though the stock opened at $37.51, the bulls momentum made the stock top out at $39.84 level for the day. The stock recorded a low of $37.51 and closed the trading day at $39.715, in the green by 8.30%. The total traded volume for the day was 965,318. The stock had closed at $36.67 in the previous days trading.

In an insider trading activity, The Securities and Exchange Commission has divulged that Davidson David, officer (Chief Medical Officer) of Bluebird Bio, Inc., had unloaded 1,000 shares at an average price of $40.11 in a transaction dated on June 15, 2016. The total value of the transaction was worth $40,110.

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.